This bill requires the Secretary of Health and Human Services to create draft guidance for developing non-addictive pain medications within one year of the law's enactment. The guidance would address how pharmaceutical companies can develop and bring to market non-addictive alternatives to treat chronic pain, filling a gap in current regulatory direction. The measure affects pharmaceutical manufacturers, pain patients, and healthcare providers who could benefit from safer pain management options with lower addiction risks. There is no specific funding amount mentioned in the legislation, as it primarily directs an executive agency to issue guidance using existing authority. The bill was introduced in December 2023 with bipartisan support and was referred to the Senate Health, Education, Labor, and Pensions Committee.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.